Compare General Dynamics Corporation (GD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Viatris Inc — how do they compare? General Dynamics Corporation trades at $394.49 (market cap $106.03B), while Viatris Inc trades at $16.15 (market cap $18.69B). The key difference: General Dynamics Corporation is far larger — about 5.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| GD | VTRS | |
|---|---|---|
Market Cap | $106.03B | $18.69B |
Sector | Industrials | Health |
52-Week High | $395.97 | $17.86 |
52-Week Low | $312.53 | $9.49 |
Enterprise Value | $111.17B | $30.80B |
Dividend Yield | 1.62% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $392.68, down 0.83% on the day, amid strong fundamental performance with Q2 2026 EPS beating estimates at $4.24 versus $3.96 expected. The stock shows bullish technical signals with moving averages supporting upward momentum, while fundamentals reveal robust revenue growth to $52.55 billion in 2025 and improving profit margins. Recent contract wins including a $29.5 billion submarine award and a $1.3 billion cybersecurity contract highlight ongoing defense sector strength.
The outlook remains positive with analyst consensus pointing to 8.7% upside to the $427.40 price target, though valuation multiples appear elevated. Key risks include defense budget uncertainties and competitive pressures, while institutional sentiment remains bullish with 57% buy ratings. The company's strong backlog of $136.5 billion provides visibility for future growth.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
